Avanir Pharmaceuticals, Inc.
is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.

Press Releases

Avanir Pharmaceuticals Announces FDA Approval of ONZETRA™ Xsail™ (AVP-825) for the Acute Treatment of Migraine in Adults
Jan 28, 2016
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as President and Chief Executive Officer
Jan 20, 2016
Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms and Use of...
Dec 1, 2015